BIOMAT Database Logo BIOMAT Database Logo

Day-case transfer for percutaneous coronary intervention with adjunctive abciximab in acute coronary syndromes. 2002

D J Blackman, and N R Clarke, and W P Orr, and E Wilkinson, and A Beswick, and D Coppock, and D C Sprigings, and A P Banning

UI MeSH Term Description Entries
D007140 Immunoglobulin Fab Fragments Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN. Fab Fragment,Fab Fragments,Ig Fab Fragments,Immunoglobulins, Fab Fragment,Fab Immunoglobulin Fragments,Immunoglobulin Fab Fragment,Immunoglobulins, Fab,Fab Fragment Immunoglobulins,Fab Fragment, Immunoglobulin,Fab Fragments, Immunoglobulin,Fragment Immunoglobulins, Fab,Fragment, Fab,Immunoglobulin Fragments, Fab
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010360 Patient Transfer Interfacility or intrahospital transfer of patients. Intrahospital transfer is usually to obtain a specific kind of care and interfacility transfer is usually for economic reasons as well as for the type of care provided. Patient Dumping,Care Transition,Health Care Transition,Patient Transition,Patient Turfing,Transition of Care,Care Transition, Health,Care Transitions,Care Transitions, Health,Dumping, Patient,Health Care Transitions,Patient Transfers,Patient Transitions,Patient Turfings,Transfer, Patient,Transfers, Patient,Transition, Care,Transition, Health Care,Transition, Patient,Transitions, Care,Transitions, Health Care,Transitions, Patient,Turfing, Patient,Turfings, Patient
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D012017 Referral and Consultation The practice of sending a patient to another program or practitioner for services or advice which the referring source is not prepared to provide. Consultation,Gatekeepers, Health Service,Hospital Referral,Second Opinion,Consultation and Referral,Health Service Gatekeepers,Hospital Referrals,Referral,Referral, Hospital,Referrals, Hospital,Consultations,Gatekeeper, Health Service,Health Service Gatekeeper,Opinion, Second,Opinions, Second,Referrals,Second Opinions
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D003631 Day Care, Medical Institutional health care of patients during the day. The patients return home at night. Day Care,Hospitalization, Partial,Care, Day,Medical Day Care,Partial Hospitalization
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

D J Blackman, and N R Clarke, and W P Orr, and E Wilkinson, and A Beswick, and D Coppock, and D C Sprigings, and A P Banning
Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.
April 2001, The Journal of invasive cardiology,
D J Blackman, and N R Clarke, and W P Orr, and E Wilkinson, and A Beswick, and D Coppock, and D C Sprigings, and A P Banning
Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab.
September 2001, Mayo Clinic proceedings,
D J Blackman, and N R Clarke, and W P Orr, and E Wilkinson, and A Beswick, and D Coppock, and D C Sprigings, and A P Banning
Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction.
February 2007, Mayo Clinic proceedings,
D J Blackman, and N R Clarke, and W P Orr, and E Wilkinson, and A Beswick, and D Coppock, and D C Sprigings, and A P Banning
Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction.
January 2003, International journal of clinical practice,
D J Blackman, and N R Clarke, and W P Orr, and E Wilkinson, and A Beswick, and D Coppock, and D C Sprigings, and A P Banning
Overview of glycoprotein IIb/IIIa clinical trials with abciximab and eptifibatide in acute coronary syndromes and percutaneous coronary intervention.
December 1999, The Journal of invasive cardiology,
D J Blackman, and N R Clarke, and W P Orr, and E Wilkinson, and A Beswick, and D Coppock, and D C Sprigings, and A P Banning
Percutaneous coronary intervention with adjunctive abciximab and clopidogrel in a patient with chronic idiopathic thrombocytopaenic purpura.
March 2001, International journal of cardiovascular interventions,
D J Blackman, and N R Clarke, and W P Orr, and E Wilkinson, and A Beswick, and D Coppock, and D C Sprigings, and A P Banning
Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes.
September 2001, Current cardiology reports,
D J Blackman, and N R Clarke, and W P Orr, and E Wilkinson, and A Beswick, and D Coppock, and D C Sprigings, and A P Banning
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
April 2006, JAMA,
D J Blackman, and N R Clarke, and W P Orr, and E Wilkinson, and A Beswick, and D Coppock, and D C Sprigings, and A P Banning
Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions.
November 2006, Circulation,
D J Blackman, and N R Clarke, and W P Orr, and E Wilkinson, and A Beswick, and D Coppock, and D C Sprigings, and A P Banning
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.
January 2010, European heart journal,
Copied contents to your clipboard!